Merck is constructing a $1 billion drug manufacturing facility in Wilmington, Delaware, as part of its commitment to investment and growth in the United States.

"The Merck Wilmington Biotech site represents our continued commitment to growing our investments in U.S. manufacturing and has the potential to create thousands of high-paying American jobs while ...

Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US. The 470,000ft² facility is set to bolster the company's biologics and ...

Merck, known as MSD outside of the United States and Canada, announced the start of construction for a $1 billion, 470,000-square-foot state-of-the-art biologics center of excellence in Wilmington, ...

Merck offers a 4.2% dividend yield but faces uncertainty with KEYTRUDA's LOE. Click here to find out why MRK stock is a Hold.

(RTTNews) - Merck & Co., Inc. (MRK), Tuesday announced that the company has started construction of state-of-the-art biologics center of excellence worth $1 billion in Wilmington, Delaware ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Donald Trump's tariffs.

Merck plans to complete labs at the former DuPont Co. Chestnut Run research and production site at 984 Centre Rd. in Wilmington by 2028 and add manufacturing and offices by 2030.

Merck, known as MSD outside of the United States and Canada, has started construction on a $1bn, 470,000-square-foot state-of-the-art biologics center of excellence in Wilmington, Delaware.

"The Merck Wilmington Biotech site represents our continued commitment to growing our investments in U.S. manufacturing and has the potential to create thousands of high-paying American jobs while ...

Merck, known as MSD outside of the United States and Canada, announced the start of construction for a $1 billion, 470,000-square-foot state-of-the-art biologics center of excellence in Wilmington, ...